Source - RNS
RNS Number : 3078J
Premaitha Health PLC
08 September 2016

Premaitha Health plc

("Premaitha" or the "Company")

Directorate Change

Manchester, UK - 8 September 2016 - Premaitha Health plc (AIM: NIPT), developer of the leading CE-marked complete non-invasive prenatal screening system, announces that David Evans, Non-executive Chairman, has stepped down from the Board with immediate effect. Adam Reynolds, Non-executive Director, will become Non-executive Chairman on an interim basis until such time as a new permanent chairman is appointed.


Adam Reynolds, Non-executive Chairman, commented:


"On behalf of the Board I would like to thank David Evans for his enormous contribution to Premaitha. David has provided valuable counsel since the Company's admission to AIM in 2014 and leading up to our successful commercialisation of the IONA® test, which is now being used in multiple countries around the world as a safe and fast non-invasive prenatal screening system."


The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.


For more information, please contact:


Premaitha Health plc

Tel: +44 (0) 161 667 6865

Dr Stephen Little, Chief Executive Office


Barry Hextall, Chief Financial Officer

Joanne Cross, Head of Marketing


[email protected]




Cairn Financial Advisers LLP (Nomad)

Tel: +44 (0) 20 7148 7900

Liam Murray




Panmure Gordon (UK) Limited (Joint Broker)

Tel: +44 (0) 20 7886 2500

Freddy Crossley (Corporate Finance) / Maisie Rose Atkinson (Sales)




finnCap (Joint Broker)

Tel: +44 (0) 20 7220 0500

Adrian Hargrave / Scott Mathieson (Corporate Finance)


Tony Quirke (Corporate Broking)




Vigo Communications

Tel: +44 (0) 20 7830 9700

Ben Simons / Fiona Henson / Antonia Pollock


[email protected]



About Premaitha


Premaitha is a molecular diagnostics company which uses the latest advances in DNA analysis technology to develop safer, faster and regulatory approved non-invasive screening tests for pregnant women.


Premaitha's lead test - the IONA® test - was launched in February 2015 and is the leading CE marked complete system which estimates the risk of a fetus being affected with Down's syndrome or other genetic conditions. The IONA® test is performed on the mother's blood sample - which contains traces of fetal DNA - and then analysed using next generation DNA sequencing technology from ThermoFisher Scientific.


Unlike existing prenatal screening methods, due to its high level of accuracy, the IONA® test can significantly reduce the number of women subjected to unnecessary stressful and invasive follow-up diagnostic procedures which are costly, resource intensive and carry a risk of miscarriage.


Non-invasive prenatal screening is an emerging, multi-billion dollar global market and Premaitha's complete CE marked system enables laboratories and health care practitioners to offer an approved, non-invasive prenatal screening system in-house. 


Premaitha is based in Manchester Science Park, United Kingdom and its shares trade on the AIM market of the London Stock Exchange (AIM: NIPT). For further information please visit Follow us on twitter @PremaithaHealth.




This information is provided by RNS
The company news service from the London Stock Exchange

Related Charts

Premaitha Health (NIPT)

0.00 (0.00%)
delayed 18:15PM